PokerTek (PTEK) to Present at the 5th Annual LD MICRO Growth Conference

MATTHEWS, N.C., Dec. 3, 2012 /PRNewswire/ — PokerTek, Inc. (NASDAQ: PTEK) announced today that Mark Roberson, Chief Executive Officer, will present at the 5th Annual LD MICRO Growth Conference on Wednesday, December 5th at 3:30 pm PST / 6:30 pm EST. The conference is being held at the Luxe Sunset Bel Air Hotel in Los Angeles, California.

“We are pleased to be invited to present at the LD MICRO Growth Conference,” commented Mark Roberson. “LD MICRO brings together more than 140 presenting companies and 200 institutions focused on investing in small and micro-cap companies.

“With our growth accelerating, I look forward to reintroducing PokerTek to the investing community.”

“We are honored to have PokerTek presenting at our 5th annual event,” said LD MICRO President Chris Lahiji.

About LD MICRO

LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.

About PokerTek, Inc.:

PokerTek, Inc. (NASDAQ:PTEK) is a licensed gaming company headquartered in Matthews, NC that develops and markets electronic table game solutions for the gaming industry. www.PokerTek.com

Contact:
Mark Roberson
CEO and CFO
PokerTek, Inc.
704.849.0860, x101
investorrelations@pokertek.com

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are made in accordance with the Private Securities Litigation Reform Act of 1995. Our actual results may differ materially from those implied in these forward-looking statements as a result of many factors, including, but not limited to, the impact of global macroeconomic and credit conditions on our business and the business of our suppliers and customers, overall industry environment, customer acceptance of our products, delay in the introduction of new products, further approvals of regulatory authorities, adverse court rulings, production and/or quality control problems, the denial, suspension or revocation of permits or licenses by regulatory or governmental authorities, termination or non-renewal of customer contracts, competitive pressures, and our financial condition, including our ability to maintain sufficient liquidity to operate our business. These and other risks and uncertainties are described in more detail in our most recent annual report on Form 10-K and other reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. We undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by applicable laws, and you are urged to review and consider disclosures that we make in the reports that we file with the Securities and Exchange Commission that discuss other factors germane to our business.

ExploreLearning (ABCD) Reflex Tops One Billion Facts Solved

CHARLOTTESVILLE, Va., Dec. 3, 2012 /PRNewswire/ — ExploreLearning, a division of Cambium Learning Group, Inc. (Nasdaq: ABCD), announced that students have now solved over one billion addition, subtraction, multiplication and division facts using Reflex. ExploreLearning Reflex is a research-based program that uses the allure of challenging and exciting games to get students engaged and working at peak performance in developing instant recall of math facts.

Reflex launched in April 2011, just 20 months ago, but is already being used by hundreds of thousands of students in all 50 states.

“Reflex is succeeding in solving the problems associated with math fact fluency in this country,” says Paul Cholmsky, vice president of research and development at ExploreLearning. “Times table drills, flashcards and timed worksheets are not only boring, they also don’t work very well for many students. As a result, these students might decide they aren’t ‘good’ at math. Reflex is playing a part in reversing that trend, helping students across the country confidently master over a million new facts a week, while having a great time doing it.”

Behind the games is a combination of sophisticated technology and pedagogy that stems from R&D that ExploreLearning began in 2004 under a series of National Science Foundation Small Business Innovation Research grants. Reflex is the company’s first product based on this research, which explored how games and simulations can serve as new kinds of sensors. These sensors enable new types of pedagogically-relevant behaviors to be data mined, monitored, and analyzed.

Embedding these sensors within a series of interactive online learning experiences enables detailed information about individual progress to be collected on a large scale.  This rich data can then be analyzed and used to drive optimization of the learning system.  Students have now mastered over 21 million facts using Reflex, and ExploreLearning continues to evolve and improve the system’s instructional logic with each day’s new data.

Pairing this innovative software system with highly-engaging games has been the other factor in the product’s runaway success.

Cholmsky says, “Students enjoy Reflex so much, they even choose to use the system in their free time. We’ve studied many schools where Reflex is assigned as homework, say, three times a week, and students go well beyond that, regularly logging on five, six or even seven days a week to play games and work on their fact fluency.  Teachers are happy when the class average is to do more homework than assigned! And we get fan mail every day from students, parents, teachers and administrators.”

About ExploreLearning
ExploreLearning develops online solutions to improve student learning in math and science.  ExploreLearning currently has two products:  Gizmos, the world’s largest library of interactive, online simulations for math and science in grades 3-12; and Reflex, the most powerful solution available for math fact fluency development. Gizmos and Reflex bring research-proven instructional strategies to classrooms around the world. ExploreLearning is a Charlottesville, VA-based business unit of Cambium Learning Group, Inc. [Nasdaq:ABCD] based in Dallas, TX. For more information about Gizmos, please visit http://www.explorelearning.com. For more information about Reflex, please visit http://www.reflexmath.com.

Investor Contact:
Chris Cleveland
Investor Relations
Cambium Learning Group, Inc.
214-932-9474
chris.cleveland@cambiumlearning.com

Media Contact:
Julia Given
VP Marketing
ExploreLearning
434-293-7043 ext. 223
julia.given@explorelearning.com

Cleantech Solutions (CLNT) Purchase 157,966 Company Shares

WUXI, China, Dec. 3, 2012 /PRNewswire-FirstCall/ — Cleantech Solutions International, Inc. (“Cleantech Solutions” or “the Company”) (NASDAQ: CLNT), a manufacturer of metal components and assemblies, primarily used in the wind power, solar and other clean technology industries, today announced that the Company’s Chairman and CEO Mr. Jianhua Wu and his wife Ms. Lihua Tang have agreed to purchase 157,966 shares of the Company’s common stock for a total of $612,903 (RMB3,800,000) at $3.88 a share.

The investment will be primarily used for working capital at Wuxi Huayang Dyeing Machinery Co., Ltd., a subsidiary of Cleantech Solutions.

“With the recent flow of orders for our airflow-dyeing machines, we are optimistic about the ongoing replacement cycle in the textile industry and believe the current sale momentum will continue for the next few quarters, when we expect to see an increasing number of follow-on and larger orders as well as new orders from additional customers,” said Mr. Jianhua Wu, Chairman and CEO of Cleantech Solutions. “The additional capital will help ensure we are well positioned to meet the needs of the anticipated ramp-up in sales and to acquire additional equipment required for our operations.”

About Cleantech Solutions International

Cleantech Solutions is a manufacturer of metal components and assemblies, primarily used in clean technology industries. The Company supplies forging products, fabricated products and machining services to a range of clean technology customers, primarily in the wind power sector and supplies dyeing and finishing equipment to the textile industry. Cleantech Solutions is committed to achieving long-term growth through ongoing technological improvement, capacity expansion, and the development of a strong customer base. The Company’s website is www.cleantechsolutionsinternational.com. Any information on the Company’s website or any other website is not a part of this press release.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary and affiliated companies. These forward looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website, including factors described in “Risk Factors” in our Form 10-K for the year ended December 31, 2011 and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K for the year ended December 31, 2011 and our Form 10-Q for the quarter ended June 30, 2012. Any information on the Company’s website or any other website is not a part of this press release. All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:
Cleantech Solutions International, Inc.
Ms. Wanfen Xu, Chief Financial Officer
E-mail: xu_wf@cleantechsolutionsinternational.com
Web: www.cleantechsolutionsinternational.com

Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
E-mail: crocker.coulson@ccgir.com
Web: www.ccgirasia.com

Revolution Lighting (RVLT) To Acquire Seesmart Technologies, Inc.

Complements and Strengthens Our Position as a Leader in the LED Lighting Industry

CHARLOTTE, N.C., Dec. 3, 2012 /PRNewswire/ —

• Provides Revolution with an exclusive network of over 50 focused distributors and 300 sales representatives covering the entire United States and selected international locations.
• Establishes a Comprehensive Portfolio of Leading Products and Solutions and Significantly Enhances our Business development Capabilities.
• Adds A Significant Pipeline of Qualified Opportunities.

Revolution Lighting Technologies, Inc. (NASDAQ: RVLT), a leader in advanced LED lighting technology today announced that it has entered into a definitive agreement to acquire Seesmart Technologies, Inc. in a stock and cash transaction valued at approximately $20 million.  The transaction has been approved by both Board of Directors and is expected to close by December 31, 2012.

Seesmart based in Simi Valley, California is a leading LED solutions provider with a broad range of solutions serving the commercial, industrial and institutional lighting markets.  Seesmart’s strong leadership combined with its exclusive network of experienced lighting distributors and sales representatives provides Seesmart with a customer and solution focused advantage.  Seesmart has a group of over 50 exclusive distributors and 300 sales representatives covering virtually all of the United States and selected international locations.  In addition, it has developed centers of excellence in key US locations which are used to provide distributor training and to demonstrate lighting solutions in realistic product environments.  Seesmart has a complete end-to-end product line for both indoor and outdoor applications and is highly complementary to the existing Revolution Array product line.

“The acquisition of Seesmart is a significant step in the strategic transformation of Revolution Lighting Technologies becoming a leading quality provider of LED lighting solutions.  The LED market is entering a period of dramatic growth.  We believe a company with a broad state of the art product portfolio, a network of qualified distributors, and a reputation for superior service will be well positioned for dramatic growth in this space.  Seesmart significantly strengthens our position in all of these key areas, and we expect them to grow rapidly and be profitable in 2013 and beyond,” said Robert V. LaPenta, Chairman of Revolution.

“Our combination with Revolution Lighting and Robert LaPenta’s Aston Capital will enable us to shape the future of LED lighting through continued innovation, increased scale, and focus on developing new opportunities and top flight customer service,” said Ken Ames, Chief Executive Officer of Seesmart.

Under the terms of the agreement, Seesmart will receive approximately 50 percent of the purchase price consideration in shares of Revolution stock and 50 percent in cash.  The $10 million of stock consideration will be based on the volume weighted average price of the stock over up to 20 consecutive days ending with the second trading day preceding closing, and to the extent the number of shares would exceed 9.1 million shares, Revolution at its discretion may elect to pay the difference in cash.  The $10 million of cash consideration contemplated will be derived from the sale of a new  convertible preferred stock to RVL Holdings, an entity managed by Aston Capital, LLC and controlled by Robert V. LaPenta.  The Company will provide a more detailed description of the terms and conditions of the transaction in a Current Report on Form 8-K to be filed with the SEC.

“Seesmart has done an excellent job of penetrating the LED lighting market through its distribution/dealer network and developing a full line of products including interior and exterior lighting fixtures,” stated Mike Bauer, President and CEO of Revolution Lighting Technologies.  “The combined companies provide a significant platform in terms of both talent and technology, and we are very excited about the potential for dynamic growth this merger creates,” added Mr. Bauer.

For more information, please visit the Revolution Lighting Technologies, Inc. web site at www.rvlti.com.

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties, including the satisfaction of closing conditions  prior to the consummation of the acquisition of Seesmart and the anticipated benefits of such acquisition.  Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Reference is made to Revolution Lighting’s filings under the Securities Exchange Act for additional factors that could cause actual results to differ materially.  Revolution Lighting Technologies, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.  Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.  Readers are cautioned not to place undue reliance on these forward-looking statements.

VistaGen (VSTA) Formalizes Centre for Commercialization of Regenerative Medicine Membership

SOUTH SAN FRANCISCO, CA — (Marketwire) — 12/03/12 — VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, has formalized its membership in the Toronto-based Centre for Commercialization of Regenerative Medicine’s (CCRM) Industry Consortium.

“VistaGen’s membership reflects our strong association with CCRM and its core programs and objectives, both directly and through our strategic relationships with Dr. Gordon Keller and the University Health Network (UHN). Our long-term sponsored research agreement with Dr. Keller, UHN and UHN’s McEwen Centre for Regenerative Medicine offers both a solid foundation and unique opportunities for expanding the commercial applications of our Human Clinical Trials in a Test Tube™ platform by building multi-party collaborations with CCRM and members of its Industry Consortium,” says Shawn Singh, VistaGen CEO. “These collaborations have the potential to transform medicine and accelerate significant advances in human health and wellness that stem cell technologies and regenerative medicine promise.”

“Even before VistaGen joined CCRM’s Industry Consortium it was active in the Toronto regenerative medicine community and advising us as we prepared to launch in 2011,” explains Dr. Michael May, CEO of the Centre for Commercialization of Regenerative Medicine. “I’m confident that our relationship will grow stronger with VistaGen as a formal partner and I look forward to us working closely together on projects that will accelerate drug discovery and benefit patients.”

CCRM is a not-for-profit, public-private consortium funded by the Government of Canada, six Ontario-based institutional partners and more than 20 companies representing the key sectors of the regenerative medicine industry. CCRM supports the development of foundational technologies that accelerate the commercialization of stem cell- and biomaterials-based products and therapies. Other members of CCRM’s Industry Consortium include such leading global companies as Pfizer, GE Healthcare and Lonza.

The industry leaders that comprise the CCRM consortium benefit from proprietary access to certain licensing opportunities, academic rates on fee-for-service contracts at CCRM and opportunities to participate in large collaborative projects, among other advantages. VistaGen is especially well positioned through its existing relationships with key members.

Gordon Keller, Ph.D. is Director of the McEwen Centre for Regenerative Medicine at UHN. A CCRM partner, the McEwen Centre is a world-renowned centre for stem cell biology and regenerative medicine and a world-class stem cell research facility. He is also a Professor at the University of Toronto in the Department of Medical Biophysics and Senior Scientist of the Ontario Cancer Institute in Toronto. Dr. Keller’s lab is one of the world leaders in successfully applying principles from the study of developmental biology of many animal systems to the differentiation of pluripotent stem cell systems, resulting in reproducible, high-yield production of human heart, liver, blood and vascular cells. The results and procedures developed in Dr. Keller’s lab are often quoted and used by academic scientists worldwide.

UHN, a major landmark in Canada’s healthcare system, is one of the world’s largest research hospitals, with major research in transplantation, cardiology, neurosciences, oncology, surgical innovation, infectious diseases and genomic medicine. Providing care to the community for more than two centuries, UHN brings together the talent and resources needed to achieve global impact and provide exemplary patient care, research and education.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen’s drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories after substantial investment and development due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

Additionally, VistaGen’s small molecule drug candidate, AV-101, is completing Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen’s Facebook page at http://www.facebook.com/VistaGen

Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen’s stem cell technology-based predictive toxicology and metabolism screening and drug rescue activities, its AV-101 Phase 1 clinical program, its ability to enter into predictive toxicology, metabolism screening and/or drug rescue collaborations and/or licensing arrangements with respect to one or more drug rescue variants, risks and uncertainties relating to the availability of substantial additional capital to support its research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to AV-101 and any drug rescue variant identified and developed by VistaGen. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For more information:

Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975